Biomarker-stratified first-line treatment of right-sided metastatic colon cancer with interdisciplinary collaboration in the IVOPAK II trial
Francesco Vitali(Friedrich-Alexander-Universität Erlangen-Nürnberg), Axel Wein(Friedrich-Alexander-Universität Erlangen-Nürnberg), Susanne Merkel(Friedrich-Alexander-Universität Erlangen-Nürnberg), Axel Schmid(Universitätsklinikum Erlangen), Robert Grützmann(University Hospital Carl Gustav Carus), Markus Eckstein(Friedrich-Alexander-Universität Erlangen-Nürnberg), Arndt Hartmann(Friedrich-Alexander-Universität Erlangen-Nürnberg), Robert Stöhr(Friedrich-Alexander-Universität Erlangen-Nürnberg), Stephan Kersting(Universitätsmedizin Greifswald), Christoph Schubart(Friedrich-Alexander-Universität Erlangen-Nürnberg)
Cited by 0
Related Papers
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
|Cancer Cell|2016|660
Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial
|The Lancet|2020|593
Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12
|Journal of Clinical Oncology|2019|550
Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis
|The American Journal of Surgical Pathology|2005|411